This report summarizes efforts undertaken in the area of drug delivery, with a look at further efforts made in the area of bacterial cellulose (BC) biomedical applications in general. There are many current methodologies (past and present) for the creation of BC membrane composites custom-engineered with drug delivery functionality, with brief consideration for very close applications within the broader category of biomedicine. The most emphasis was placed on the crucial aspects that open the door to the possibility of drug delivery or the potential for use as drug carriers. Additionally, consideration has been given to laboratory explorations as well as already established BC-drug delivery systems (DDS) that are either on the market commercially or have been patented in anticipation of future commercialization. The cellulose producing strains, current synthesis and growth pathways, critical aspects and intrinsic morphological features of BC were given maximum consideration, among other crucial aspects of BC DDS.
A “super” bioactive antibacterial hydrogel, Icariin-β-CD-inclusion complex/Bacterial cellulose and an equally capable counterpart Icariin-Bacterial cellulose (ICBC) were successfully produced with excellent antioxidant properties. The highly porous hydrogels demonstrated very high fluid/liquid absorption capability and were functionally active as Fourier Transform Infrared Spectrometer (FTIR) test confirmed the existence of abundant hydroxyls (-OH stretching), carboxylic acids (-CH2/C-O stretching), Alkyne/nitrile (C≡C/C≡N stretching with triple bonds) and phenol (C-H/N-O symmetric stretching) functional groups. Scanning electron microscope (SEM) and X-ray diffraction (XRD) tests confirmed a successful β-CD-inclusion complexation with Icariin with a great potential for sustained and controlled drug release. In vitro drug release test results indicated a systemic and controlled release of the drug (Icariin) from the internal cavities of the β-CD inclusion complex incorporated inside the BC matrix with high Icariin (drug) release rates. Impressive inactivation rates against Gram-negative bacteria Escherichia coli ATCC 8099 and gram-positive bacteria Staphylococcus aureus ATCC 6538; >99.19% and >98.89% respectively were recorded, as the materials proved to be non-toxic on L929 cells in the in vitro cytotoxicity test results. The materials with promising versatile multipurpose administration of Icariin for wound dressing (as wound dressers), can also be executed as implants for tissue regeneration, as well as face-mask for cosmetic purposes.
About Me
Research focus: functional textiles and nanomaterials for biomedical applications
Research focus: functional textiles and nanomaterials for biomedical applications